Literature DB >> 11159184

The characterization of mice with a targeted combined deficiency of protein c and factor XI.

J C Chan1, J G Ganopolsky, I Cornelissen, M A Suckow, M J Sandoval-Cooper, E C Brown, F Noria, D Gailani, E D Rosen, V A Ploplis, F J Castellino.   

Abstract

Activated protein C functions directly as an anticoagulant and indirectly as a profibrinolytic enzyme. To determine whether the fibrin deposition previously observed in PC(-/-) murine embryos and neonates was mediated through the FXI pathway, PC(+/-)/FXI(-/-) mice were generated and crossbred to produce double-deficient progeny (PC(-/-)/FXI(-/-)). PC(-/-)/FXI(-/-) mice survived the early lethality observed in the PC(-/-)/FXI(+/+) neonates, with the oldest PC(-/-)/FXI(-/-) animal living to 3 months of age. However, the majority of these animals was sedentary and significantly growth-retarded. On sacrifice or natural death, all of these PC(-/-)/FXI(-/-) mice demonstrated massive systemic fibrin deposition with concomitant hemorrhage and fibrosis, as confirmed through histological analyses. Several of these animals also presented with enlarged lymph nodes and extensive lymphatic fluid in the thoracic cavity. Thus, although a number of the PC(-/-)/FXI(-/-) mice survived the lethal perinatal coagulopathy seen in the PC(-/-) neonates, they nonetheless succumbed to overwhelming thrombotic disease in later life. This combined deficiency state provided the first clear indication that the course of a severe thrombotic disorder could be manipulated by blocking the intrinsic pathway and provided the first opportunity to study a total protein C deficiency in an adult animal.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159184      PMCID: PMC1850297          DOI: 10.1016/S0002-9440(10)63989-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  28 in total

1.  Regulation of murine protein C gene expression in vivo: effects of tumor necrosis factor-alpha, interleukin-1, and transforming growth factor-beta.

Authors:  K Yamamoto; T Shimokawa; T Kojima; D J Loskutoff; H Saito
Journal:  Thromb Haemost       Date:  1999-10       Impact factor: 5.249

2.  Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.

Authors:  F B Taylor; A Chang; C T Esmon; A D'Angelo; S Vigano-D'Angelo; K E Blick
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

3.  TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex.

Authors:  L Bajzar; J Morser; M Nesheim
Journal:  J Biol Chem       Date:  1996-07-12       Impact factor: 5.157

4.  Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit.

Authors:  J C Chan; P Carmeliet; L Moons; E D Rosen; Z F Huang; G J Broze; D Collen; F J Castellino
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

5.  The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation.

Authors:  L Bajzar; M Nesheim
Journal:  J Biol Chem       Date:  1993-04-25       Impact factor: 5.157

6.  Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice.

Authors:  L R Jalbert; E D Rosen; L Moons; J C Chan; P Carmeliet; D Collen; F J Castellino
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

7.  Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses.

Authors:  W W Hancock; S T Grey; L Hau; E Akalin; C Orthner; M H Sayegh; H H Salem
Journal:  Transplantation       Date:  1995-12-27       Impact factor: 4.939

8.  Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats.

Authors:  K Murakami; K Okajima; M Uchiba; M Johno; T Nakagaki; H Okabe; K Takatsuki
Journal:  Blood       Date:  1996-01-15       Impact factor: 22.113

9.  Physiological consequences of loss of plasminogen activator gene function in mice.

Authors:  P Carmeliet; L Schoonjans; L Kieckens; B Ream; J Degen; R Bronson; R De Vos; J J van den Oord; D Collen; R C Mulligan
Journal:  Nature       Date:  1994-03-31       Impact factor: 49.962

10.  Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester.

Authors:  S T Grey; A Tsuchida; H Hau; C L Orthner; H H Salem; W W Hancock
Journal:  J Immunol       Date:  1994-10-15       Impact factor: 5.422

View more
  9 in total

Review 1.  Factor XI and contact activation as targets for antithrombotic therapy.

Authors:  D Gailani; C E Bane; A Gruber
Journal:  J Thromb Haemost       Date:  2015-06-16       Impact factor: 5.824

Review 2.  Factor XI as a Therapeutic Target.

Authors:  David Gailani; Andras Gruber
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-05-12       Impact factor: 8.311

3.  Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis.

Authors:  B Isermann; S B Hendrickson; M Zogg; M Wing; M Cummiskey; Y Y Kisanuki; M Yanagisawa; H Weiler
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

4.  The kunitz protease inhibitor domain of protease nexin-2 inhibits factor XIa and murine carotid artery and middle cerebral artery thrombosis.

Authors:  Wenman Wu; Hongbo Li; Duraiswamy Navaneetham; Zachary W Reichenbach; Ronald F Tuma; Peter N Walsh
Journal:  Blood       Date:  2012-06-06       Impact factor: 22.113

5.  Beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I.

Authors:  Tong Shi; G Michael Iverson; Jian C Qi; Keith A Cockerill; Matthew D Linnik; Pamela Konecny; Steven A Krilis
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-08       Impact factor: 11.205

6.  Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis.

Authors:  Erik I Tucker; David Gailani; Sawan Hurst; Qiufang Cheng; Stephen R Hanson; András Gruber
Journal:  J Infect Dis       Date:  2008-07-15       Impact factor: 5.226

7.  P1 and P2' site mutations convert protease nexin-2 from a factor XIa inhibitor to a plasmin inhibitor.

Authors:  Duraiswamy Navaneetham; Wenman Wu; Hongbo Li; Dipali Sinha; Ronald F Tuma; Peter N Walsh
Journal:  J Biochem       Date:  2012-11-20       Impact factor: 3.387

8.  Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Anh T P Ngo; Kelley R Jordan; Paul A Mueller; Matthew W Hagen; Stéphanie E Reitsma; Cristina Puy; Alexey S Revenko; Christina U Lorentz; Erik I Tucker; Quifang Cheng; Monica T Hinds; Sergio Fazio; Brett P Monia; David Gailani; András Gruber; Hagai Tavori; Owen J T McCarty
Journal:  J Thromb Haemost       Date:  2021-02-10       Impact factor: 5.824

9.  A non-circulating pool of factor XI associated with glycosaminoglycans in mice.

Authors:  Bassem M Mohammed; Qiufang Cheng; Anton Matafonov; Ingrid M Verhamme; Jonas Emsley; Keith R McCrae; Owen J T McCarty; Andras Gruber; David Gailani
Journal:  J Thromb Haemost       Date:  2019-06-17       Impact factor: 16.036

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.